| Interferon alpha | melanoma, in all type of patients | vs observation | progression or death (progression free survival PFS) by 13% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| distant metastasis free survival | 0.91 [0.80 1.02] | p=1.00 | 0 | -36 | 2 | EORTC18952 (Eggermont), EORTC18991 (Eggermont), | | death (overall survival) | 0.93 [0.84 1.03] | p=1.00 | 0 | -72 | 4 | EORTC18871/DKG 80-1 (Kleeberg), EORTC18952 (Eggermont), EORTC18991 (Eggermont), Nordic IFN Trial, | | progression or death (progression free survival PFS) | 0.87 [0.79 0.96] | p=0.04 | 0 | -72 | 4 | EORTC18871/DKG 80-1 (Kleeberg), EORTC18952 (Eggermont), EORTC18991 (Eggermont), Nordic IFN Trial, |
| Trial | Studied treatment | Control | Patients |
|---|
| EORTC18871/DKG 80-1 (Kleeberg), 2004 | rIFN-alpha2b | observation | High-risk stage II patients (thickness >3 mm) and stage III patients (positivelymph nodes) without distant metastasis | | EORTC18952 (Eggermont), 2005 | | | patients who had had a thick primary tumour (thickness4 mm) resected (stage IIb) or regional lymph node metastases dissected (stage III) | | EORTC18991 (Eggermont), 2008 | pegylated interferon alfa-2b 6 mug/kg per week for 8 weeks (induction) then 3 mug/kg per week (maintenance) for an intended duration of 5 years | | patients with resected stage III melanoma | | Nordic IFN Trial, 2011 | intermediate-dose interferon alfa-2b duration 1 | duration 2 | patients with stage IIB-IIC or III resected cutaneous melanoma. |
| |
| Interferon alpha | melanoma, in adjuvant setting | vs observation | progression or death (progression free survival PFS) by 13% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| distant metastasis free survival | 0.91 [0.80 1.02] | p=1.00 | 0 | -36 | 2 | EORTC18952 (Eggermont), EORTC18991 (Eggermont), | | death (overall survival) | 0.93 [0.84 1.03] | p=1.00 | 0 | -72 | 4 | EORTC18871/DKG 80-1 (Kleeberg), EORTC18952 (Eggermont), EORTC18991 (Eggermont), Nordic IFN Trial, | | progression or death (progression free survival PFS) | 0.87 [0.79 0.96] | p=0.04 | 0 | -72 | 4 | EORTC18871/DKG 80-1 (Kleeberg), EORTC18952 (Eggermont), EORTC18991 (Eggermont), Nordic IFN Trial, |
| Trial | Studied treatment | Control | Patients |
|---|
| EORTC18871/DKG 80-1 (Kleeberg), 2004 | rIFN-alpha2b | observation | High-risk stage II patients (thickness >3 mm) and stage III patients (positivelymph nodes) without distant metastasis | | EORTC18952 (Eggermont), 2005 | | | patients who had had a thick primary tumour (thickness4 mm) resected (stage IIb) or regional lymph node metastases dissected (stage III) | | EORTC18991 (Eggermont), 2008 | pegylated interferon alfa-2b 6 mug/kg per week for 8 weeks (induction) then 3 mug/kg per week (maintenance) for an intended duration of 5 years | | patients with resected stage III melanoma | | Nordic IFN Trial, 2011 | intermediate-dose interferon alfa-2b duration 1 | duration 2 | patients with stage IIB-IIC or III resected cutaneous melanoma. |
| |
